Literature DB >> 11574950

Significance of cerebrospinal fluid adenosine deaminase isoenzymes in tuberculous (TB) meningitis.

C M Schutte1, J P Ungerer, H du Plessis, C H van der Meyden.   

Abstract

Adenosine deaminase (ADA) exists as two isoenzymes, ADA(1) and ADA(2). It appears that the ADA(2) isoenzyme originates mainly from monocytes and macrophages. In tuberculous pleural effusions most of the ADA activity consists of ADA(2). The aim of this prospective study was to analyse ADA isoenzymes in the CSF of patients with meningitis to investigate whether the expected rise of the ADA(2) isoenzyme would occur in tuberculous meningitis. ADA isoenzyme analysis was performed on the CSF of 15 patients with tuberculous and 11 patients with bacterial meningitis by an automated kinetic enzyme coupled assay in the presence and absence of a specific ADA inhibitor. The ratio of ADA(2)/ADA(Total) was > 0.8 in 14/15 patients with tuberculous meningitis. In bacterial meningitis the ratio was > or =0.8 in 10/11 patients. The ADA(2) isoenzyme is the major contributor to increased ADA activity in the CSF of patients with tuberculous meningitis, probably reflecting the monocyte-macrophage origin of the ADA. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11574950      PMCID: PMC6807738          DOI: 10.1002/jcla.1033

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  6 in total

1.  Serum and pleural adenosine deaminase activity. Correct interpretation of the findings.

Authors:  C Gakis; G M Calia; A G Naitana; A R Ortu; A Contu
Journal:  Chest       Date:  1991-06       Impact factor: 9.410

2.  Lymph node biopsy as an aid in the diagnosis of intracranial tuberculosis.

Authors:  C M Schutte; C H Van der Meyden; J H Labuscagne; D Otto
Journal:  Tuber Lung Dis       Date:  1996-06

3.  Evaluation of adenosine deaminase activity and antibody to Mycobacterium tuberculosis antigen 5 in cerebrospinal fluid and the radioactive bromide partition test for the early diagnosis of tuberculosis meningitis.

Authors:  Y M Coovadia; A Dawood; M E Ellis; H M Coovadia; T M Daniel
Journal:  Arch Dis Child       Date:  1986-05       Impact factor: 3.791

4.  Kinetic determination of serum adenosine deaminase.

Authors:  H M Oosthuizen; J P Ungerer; S H Bissbort
Journal:  Clin Chem       Date:  1993-10       Impact factor: 8.327

5.  Serum adenosine deaminase: isoenzymes and diagnostic application.

Authors:  J P Ungerer; H M Oosthuizen; S H Bissbort; W J Vermaak
Journal:  Clin Chem       Date:  1992-07       Impact factor: 8.327

6.  Significance of adenosine deaminase activity and its isoenzymes in tuberculous effusions.

Authors:  J P Ungerer; H M Oosthuizen; J H Retief; S H Bissbort
Journal:  Chest       Date:  1994-07       Impact factor: 9.410

  6 in total
  5 in total

Review 1.  Central nervous system tuberculosis.

Authors:  A Cherian; S V Thomas
Journal:  Afr Health Sci       Date:  2011-03       Impact factor: 0.927

Review 2.  Central nervous system tuberculosis: pathogenesis and clinical aspects.

Authors:  R Bryan Rock; Michael Olin; Cristina A Baker; Thomas W Molitor; Phillip K Peterson
Journal:  Clin Microbiol Rev       Date:  2008-04       Impact factor: 26.132

3.  Cryptococcal meningitis associated with increased adenosine deaminase in the cerebrospinal fluid.

Authors:  Yuji Tanaka; Kazuo Satomi
Journal:  Springerplus       Date:  2016-12-12

4.  The dubious value of cerebrospinal fluid adenosine deaminase measurement for the diagnosis of tuberculous meningitis.

Authors:  Pieter Ekermans; Adriano Dusé; Jaya George
Journal:  BMC Infect Dis       Date:  2017-01-31       Impact factor: 3.090

5.  Serum Biomarker Profile Including CCL1, CXCL10, VEGF, and Adenosine Deaminase Activity Distinguishes Active From Remotely Acquired Latent Tuberculosis.

Authors:  Eveline M Delemarre; Laura van Hoorn; Aik W J Bossink; Julia Drylewicz; Simone A Joosten; Tom H M Ottenhoff; Onno W Akkerman; Delia Goletti; Elisa Petruccioli; Assunta Navarra; Brigitte T A van den Broek; Sanne P A Paardekooper; Ineke van Haeften; Leo Koenderman; Jan-Willem J Lammers; Steven F T Thijsen; Regina W Hofland; Stefan Nierkens
Journal:  Front Immunol       Date:  2021-10-07       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.